Pneumococcal vaccine response in cirrhosis and liver transplantation

T. M. McCashland, L. C. Preheim, Martha J. Gentry-Nielsen

Research output: Contribution to journalArticlepeer-review

146 Scopus citations


Cirrhosis is a major risk factor for severe pneumococcal infection, and patients evaluated for liver transplantation routinely receive pneumococcal vaccine. This study followed serologic antibody levels of 45 adults evaluated for transplantation and 13 age-matched control subjects. All received 23-valent pneumococcal polysaccharide vaccine (PPS). Serum anti-PPS levels and antibodies specific for capsular types 3 and 23 were measured by ELISA before and 1 and 6 months after vaccination. Antibody levels for the 25 patients who received transplants also were measured immediately before and 3 months after transplantation. Control subjects had higher IgG responses to the whole vaccine, whereas patients appeared to produce more IgM and IgA. IgA, and possibly IgM levels, also declined faster in patients than in control subjects. All anti-PPS levels were at or below prevaccination baselines by 3 months after transplantation. These data suggest that vaccination with PPS may not be effective for patients during and after liver transplantation.

Original languageEnglish (US)
Pages (from-to)757-760
Number of pages4
JournalJournal of Infectious Diseases
Issue number2
StatePublished - 2000

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Pneumococcal vaccine response in cirrhosis and liver transplantation'. Together they form a unique fingerprint.

Cite this